Portal de Periódicos da CAPES

1295 ANDROGEN DEPRIVATION THERAPY AND MORBID OBESITY: DO THEY SHARE CARDIOVASCULAR RISK THROUGH METABOLIC SYNDROME?

2011; Lippincott Williams & Wilkins; Volume: 185; Issue: 4S Linguagem: Inglês

10.1016/j.juro.2011.02.995

1527-3792

Ary Serpa Neto, Leonardo Oliveira Reis, Rodolfo Borges dos Reis, Lucas Nogueira, Eliney Ferreira Faria, Gustavo Franco Carvalhal, Marcos Tobias‐Machado,

Prostate Cancer Treatment and Research

You have accessJournal of UrologyProstate Cancer: Localized1 Apr 20111295 ANDROGEN DEPRIVATION THERAPY AND MORBID OBESITY: DO THEY SHARE CARDIOVASCULAR RISK THROUGH METABOLIC SYNDROME? Ary Serpa Neto, Leonardo O. Reis, Rodolfo B. dos Reis, Lucas Nogueira, Eliney F. Faria, Gustavo F. Carvalhal, and Marcos Tobias-Machado Ary Serpa NetoAry Serpa Neto São Paulo, Brazil More articles by this author , Leonardo O. ReisLeonardo O. Reis Campinas, Brazil More articles by this author , Rodolfo B. dos ReisRodolfo B. dos Reis Ribeirão Preto, Brazil More articles by this author , Lucas NogueiraLucas Nogueira Belo Horizonte, Brazil More articles by this author , Eliney F. FariaEliney F. Faria Barretos, Brazil More articles by this author , Gustavo F. CarvalhalGustavo F. Carvalhal Porto Alegre, Brazil More articles by this author , and Marcos Tobias-MachadoMarcos Tobias-Machado São Paulo, Brazil More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2011.02.995AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Although the use of androgen deprivation therapy (ADT) has resulted in improved survival in men with advanced prostate cancer, the resulting hypogonadism is associated with profound adverse effects comparable to those found in morbid obesity, being cardiovascular risk among the most lethal. Evaluate metabolic syndrome, metabolic abnormalities and cardiovascular risk in patients with prostate cancer under ADT, not under ADT and morbid obese men. METHODS This is a cross-sectional study that involves 79 men presenting prostate cancer, of whom 54 under ADT and 25 not under ADT and 91 morbidly obese patients paired by sex and age. To define metabolic syndrome, we used the International Diabetes Federation (IDF) criteria. Metabolic abnormalities, metabolic markers and Framingham score to predict the ten year coronary heart disease risk were compared among patients under ADT, not under ADT and morbid obese. RESULTS Patients under ADT presented significantly greater occurrence of diabetes and central obesity and higher levels of total cholesterol and low density lipoprotein (LDL) compared to eugonadal men (Table 1). The mean cardiovascular risk was significantly higher in patients under ADT (39.97 ± 12.53% vs. 26.09 ± 14.80%, p = 0.021). Morbidly obese and prostate cancer patients under ADT had comparable ten year coronary heart risk disease (p = 0.054). Table 1. γÇô Metabolic abnormalities and metabolic markers between prostate cancer patients under and not under androgen deprivation therapy Under ADT (n = 54) Not Under ADT (n = 25) p value Metabolic Abnormalities Hypertension⁎ 39(72.2%) 16(64.0%) 0.335 Metabolic Syndrome 29(53.7%) 6(24.0%) 0.052 Diabetes 14(25.9%) 3(12%) 0.043 Hypertrigliceridemia⁎⁎ 17(31.4%) 7(28%) 0.782 Central Obesity⁎⁎⁎ 38(70.3%) 9(36.0%) 0.008 Metabolic Markers Age (years) 73.06>7.57 73.76>8.16 0.742 Gleason score 7.25>1.27 6.60>0.54 0.064 BMI (kg/m2) 25.55>4.27 24.79>3.08 0.490 Cholesterol (mg/dL) 216.37>47.24 193.57>51.43 0.049 LDL (mg/dL) 124.58>34.26 105.92>37.07 0.038 VLDL (mg/dL) 30.50>16.68 25.76>11.62 0.073 HDL (mg/dL) 61.81>21.24 56.78>12.78 0.295 Triglicerides (mg/dL) 159.86>97.17 179.64>195.59 0.562 Fasting glucose (mg/dL) 101.76>23.40 103.78>18.97 0.747 Abdominal waist (cm) 97.48>8.39 91.23>21.40 0.031 Systolic pressure (mmHg) 130.18>13.93 131.20>15.36 0.773 Diastolic pressure (mmHg) 83.98>14.45 88.00>9.12 0.139 ⁎ defined as systolic pressure γëÑ 140 mmHg or diastolic pressure γëÑ 90 mmHg; ⁎⁎ defined as triglycerides γëÑ 150 mg/dL; ⁎⁎⁎ defined as abdominal waist γëÑ 94 cm CONCLUSIONS This study suggests that patients under ADT show higher prevalence of metabolic abnormalities and cardiovascular risk similar to those found in morbidly obese subjects. It is possible that both process share cardiovascular risk through metabolic syndrome. © 2011 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 185Issue 4SApril 2011Page: e518 Advertisement Copyright & Permissions© 2011 by American Urological Association Education and Research, Inc.MetricsAuthor Information Ary Serpa Neto São Paulo, Brazil More articles by this author Leonardo O. Reis Campinas, Brazil More articles by this author Rodolfo B. dos Reis Ribeirão Preto, Brazil More articles by this author Lucas Nogueira Belo Horizonte, Brazil More articles by this author Eliney F. Faria Barretos, Brazil More articles by this author Gustavo F. Carvalhal Porto Alegre, Brazil More articles by this author Marcos Tobias-Machado São Paulo, Brazil More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...